Shoulder pain relief without surgery? hyaluronic acid injections under study
NCT ID NCT07699406
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study investigates whether ultrasound-guided injections of low-molecular-weight hyaluronic acid (Hyalotend®) can safely reduce pain and improve shoulder function in people with chronic non-calcific supraspinatus tendinopathy. Participants receive two injections and are followed over time to track changes in pain, daily activities, and any side effects. The goal is to see if this treatment offers a non-surgical option for those who haven't found relief with physical therapy or medication.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Low-molecular-weight hyaluronic acid (Hyalotend®)
- What this could lead to
- If successful, this approach could offer a non-surgical treatment option for chronic shoulder tendon pain that hasn't improved with physical therapy or medication.
- What could go wrong
- This is a small, single-arm observational study with only 30 participants, so results may not apply broadly. The treatment may not provide lasting relief, and injection-related side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients will be recruited from the outpatient clinics of the Department of Physical Medicine and Rehabilitation at Hospital Universitario Nuestra Señora de Candelaria. Eligible participants will be patients referred to the department because of shoulder pain and/or impaired shoulder function. The diagnosis of chronic supraspinatus tendinopathy will be established by a rehabilitation physician based on the patient's medical history, physical examination, and ultrasound assessment, while excluding the presence of tendon calcifications and partial- or full-thickness tendon tears.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years. * Clinical and ultrasound-confirmed diagnosis of chronic (\>12 weeks) supraspinatus tendinopathy. * No structural tendon tear, confirmed by ultrasound. * No tendon calcification, confirmed by ultrasound. * Previous failure of conservative treatment, including physical therapy and/or analgesic or anti-inflammatory medication. * Written informed consent provided. Exclusion Criteria: * Partial- or full-thickness supraspinatus tendon tear identified by ultrasound. * Calcific supraspinatus tendinopathy identified by ultrasound. * Subacromial-subdeltoid bursitis identified by ultrasound * Previous treatment with extracorporeal focus shock wave therapy within the last 3 months. * Previous corticosteroid or platelet-rich plasma (PRP) injection within the last 3 months. * History of hypersensitivity or allergy to hyaluronic acid or any of its components. * Uncontrolled systemic disease. * Other chronic rheumatologic or autoimmune diseases. * Pregnancy or breastfeeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Supraespinatus tendinopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.